Validation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximab

References

• SiegelRNaishadhamDJemalACancer statistics, 2012CA Cancer J Clin2012621102922237781
   PubMed Web of Science ®Google Scholar
• ChesonBDFisherRIBarringtonSFRecommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classificationJ Clin Oncol201432273059306825113753
   PubMed Web of Science ®Google Scholar
• SeilerTMHiddemannWAdvances in the management of follicular lymphomaCurr Opin Oncol201224674274722960557
   PubMed Web of Science ®Google Scholar
• CultreraJLDaliaSMDiffuse large B-cell lymphoma: current strategies and future directionsCancer Control201219320421322710896
   PubMed Web of Science ®Google Scholar
• ColwellHHMathiasSDNgoNHGitlinMLuZJKnoopTThe impact of infusion reactions on oncology patients and clinicians in the inpatient and outpatient practice settings: oncology nurses’ perspectivesJ Infus Nurs200730315316017505216
   PubMedGoogle Scholar
• SchwartzbergLSStepanskiEJWalkerMSathiasSHoutsACFortnerBVImplications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter studySupport Care Cancer2009171919818592276
   PubMed Web of Science ®Google Scholar
• ChaddaSLarkinMJonesCThe impact of infusion reactions associated with monoclonal antibodies in metastatic colorectal cancer: a European perspectiveJ Oncol Pharm Pract2013191384722735081
   PubMedGoogle Scholar
• SalarAAviviIBittnerBComparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB studyJ Clin Oncol201432171782179124821885
   PubMed Web of Science ®Google Scholar
• DaviesAMerliFMihaljevicBMacDonaldDPharmacokinetics (PK), safety and overall response rate (ORR) achieved with subcutaneous (SC) administration of rituximab in combination with chemotherapy were comparable to those achieved with intravenous (IV) administration in patients (pts) with follicular lymphoma (FL) in the first-line setting: stage 1 results of the phase III SABRINA study (BO22334)Presented at: 54th ASH Annual Meeting and ExpositionDecember 8–11, 2012Atlanta, USA
   Google Scholar
• ShpilbergOJackischCSubcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidaseBr J Cancer201310961556156124002601
   PubMed Web of Science ®Google Scholar
• StilgenbauerSZenzTWinklerDSubcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study GroupJ Clin Oncol200927243994400119597025
   PubMed Web of Science ®Google Scholar
• BookbinderLHHoferAHallerMFA recombinant human enzyme for enhanced interstitial transport of therapeuticsJ Control Release2006114223024116876899
   PubMed Web of Science ®Google Scholar
• FrostGIRecombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administrationExp Opin Drug Deliv200744427440
   PubMed Web of Science ®Google Scholar
• ThomasJRWallaceMSYocumRCVaughnDEHallerMFFlamentJThe INFUSE-Morphine IIB study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illnessJ Pain Symptom Manage200938566367219819665
   PubMed Web of Science ®Google Scholar
• HarbGLebelFBattikhaJThackaraJWSafety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteersCurr Med Res Opin201026227928819947907
   PubMed Web of Science ®Google Scholar
• PivotXGligorovJMüllerVPatient preference for subcutaneous versus intravenous adjuvant trastuzumab: results of the PrefHer studyPresented at: the 13th St Gallen International Breast Cancer ConferenceMarch 13–16, 2013St Gallen, Switzerland
   Google Scholar
• MoreauPPylypenkoHGrosickiSSubcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority studyLancet Oncol201112543144021507715
   PubMed Web of Science ®Google Scholar
• YostKJThompsonCAEtonDTThe functional assessment of cancer therapy – general (FACT-G) is valid for monitoring quality of life in non-Hodgkin lymphoma patientsLeuk Lymphoma201354229029722799432
   PubMed Web of Science ®Google Scholar
• AbetzLCoombsJHKeningerDLDevelopment of the cancer therapy satisfaction questionnaire: item generation and content validity testingValue Health20058S1S41S5316336488
   PubMed Web of Science ®Google Scholar
• TraskPCTellefsenCEspindleDGetterCHsuMAPsychometric validation of the cancer therapy satisfaction questionnaireValue Health200811466967918194397
   PubMed Web of Science ®Google Scholar
• HayJLAtkinsonTMReeveBBCognitive interviewing of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)Qual Life Res201423125726923868457
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human ServicesFDA Center for Drug Evaluation and ResearchGuidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims Available from: http://ispor.org/workpaper/FDA%20PRO%20Guidance.pdfAccessed May 1, 2014
   Google Scholar
• LeidyNKVernonMPerspectives on patient-reported outcomes: content validity and qualitative research in a changing clinical trial environmentPharmacoeconomics200826536337018429654
   PubMed Web of Science ®Google Scholar
• LaschKEMarquisPVigneuxMPRO development: rigorous qualitative research as the crucial foundationQual Life Res20101981087109620512662
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyReflection Paper on the Regulatory Guidance for the Use of Health-Related Quality of Life (HRQL) Measures in the Evaluation of Medicinal Products Available from: http://ispor.org/workpaper/EMEA-HRQL-Guidance.pdfAccessed November 21, 2013
   Google Scholar
• PatrickDLBurkeLBGwaltneyCJContent validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 1 – eliciting concepts for a new PRO instrumentValue Health201114896797722152165
   PubMed Web of Science ®Google Scholar
• PatrickDLBurkeLBGwaltneyCJContent validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 2 – assessing respondent understandingValue Health201114897898822152166
   PubMed Web of Science ®Google Scholar
• EricssonKSimonHVerbal reports as dataPsychol Rev1980873215251
   Web of Science ®Google Scholar
• StreinerDLBeing inconsistent about consistency: when coefficient alpha does and doesn’t matterJ Pers Assess200380321722212763696
   PubMed Web of Science ®Google Scholar
• RummelMKimTMPlentedaCPrefmab: final analysis of patient preference for subcutaneous versus intravenous rituximab in previously untreated CD20+ diffuse large B-cell lymphoma and follicular lymphomaBlood20151263972
   Web of Science ®Google Scholar
• KnutsenAPSiegalJUnderstanding subcutaneous immunoglobulin therapies for primary immunodeficiency diseasesPharmacy Practice News: Special ReportNew YorkMcMahon Publishing2010
   Google Scholar
• CappelliniMDBejaouiMAgaogluLProspective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemiaClin Ther200729590991717697909
   PubMed Web of Science ®Google Scholar
• FallowfieldLAtkinsLCattSPatients’ preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancerAnn Oncol200617220521016239231
   PubMed Web of Science ®Google Scholar
• ScarpatoSAntivalleMFavalliEGPatient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study)Rheumatology (Oxford)201049228929419920093
   PubMed Web of Science ®Google Scholar
• AllenPBLindsayHThamTCHow do patients with inflammatory bowel disease want their biological therapy administered?BMC Gastroenterol2010101120064220
   PubMed Web of Science ®Google Scholar